Printer Friendly

Takeda advances TAK-438 into Phase III studies for treatment of acid-related diseases.

M2 PHARMA-September 19, 2011-Takeda advances TAK-438 into Phase III studies for treatment of acid-related diseases(C)2011 M2 COMMUNICATIONS

19 September 2011 - Japanese Takeda Pharmaceutical Company Limited (TYO:4502) said last Friday it had advanced TAK-438 into Phase III studies in Japan for the treatment of patients with acid-related diseases such as reflux esophagitis.

TAK-438, originated by Takeda, is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K+) to H+, K+-ATPase (proton pomp). It has a different mechanism of action from proton pump inhibitors (PPIs), the company added.

TAK-438 is anticipated to have, in clinical use, a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs, Takeda said.

The Phase III trials in Japan are multi-centric, and designed to assess the safety and efficacy of TAK-438 for diseases such as gastric ulcer, duodenal ulcer and reflux esophagitis.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:9THAI
Date:Sep 19, 2011
Words:169
Previous Article:Dynavax reports complete results from HEPLISAV Phase III study.
Next Article:Trident begins Phase Ia study of HF1020.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters